【摘要】：卵巢癌是婦科常見的惡性腫瘤,發(fā)病率高,預(yù)后差,多數(shù)患者發(fā)現(xiàn)時已是晚期,卵巢癌目前公認的治療方法是腫瘤細胞減滅手術(shù)配合化療。手術(shù)是一個損傷正氣的過程,而化療藥物作用于腫瘤細胞的同時對正常細胞也有毒性作用,引起相應(yīng)的毒副反應(yīng),主要表現(xiàn)有骨髓抑制、消化道反應(yīng)、神經(jīng)毒性等,使機體難以耐受甚至不得不中斷治療。近年來,中醫(yī)中藥相關(guān)治療的研究也越來越多,在治療腫瘤化療后的毒副反應(yīng)上有一定療效,能夠幫助機體提高免疫力,更好的配合治療。就近幾年中醫(yī)在治療卵巢癌術(shù)后化療后的臨床研究上,本文對其作了一個文獻型研究。 目的：通過對近年有關(guān)中醫(yī)治療卵巢癌術(shù)后化療后的文獻進行研究,探討中醫(yī)對卵巢癌術(shù)后化療后病機的認識,以及中藥治療的用藥規(guī)律。 方法：以CNKI知識數(shù)據(jù)庫、萬方數(shù)據(jù)知識平臺、維普中文科技期刊數(shù)據(jù)庫為檢索工具,搜索1990年1月至2014年2月有關(guān)卵巢癌的中醫(yī)臨床研究文獻,篩選出中醫(yī)結(jié)合卵巢癌化療的臨床文獻。對文獻中所用的中藥以類別、功效、性味、歸經(jīng)、頻率等內(nèi)容建立數(shù)據(jù)庫,運用Excel軟件建立數(shù)據(jù)庫并進行分類統(tǒng)計。 結(jié)果：根據(jù)資料來源及檢索方法,共獲得124篇文獻,依照本文前面所述納入標準,篩選出符合標準的文獻27篇,所有文獻中涉及病例數(shù)1201例,收集方劑共35首,所用藥物116味,藥物共出現(xiàn)410次,所使用次數(shù)14225人次。 1.根據(jù)文獻中出現(xiàn)的證型看,卵巢癌術(shù)后化療后患者以氣陰兩虛型最多,達35.22%,其次是氣虛血瘀型21.4%,脾虛濕困型17.24%。 2.根據(jù)所使用藥物頻率得出,藥物使用率排名前10位依次為黃芪、白術(shù)、茯苓、黨參、甘草、白花蛇舌草、半枝蓮、當歸、薏苡仁、莪術(shù)。 3.根據(jù)藥物歸類看,藥物出現(xiàn)次數(shù)最多的為補虛藥,占38.29%；其次是清熱藥,占15.61%；活血化瘀藥占12.93%。 4.根據(jù)藥物藥性及歸經(jīng)看,出現(xiàn)最多的藥性為平性藥,藥味為甘味,歸經(jīng)最多的為脾經(jīng)。 結(jié)論：卵巢癌術(shù)后化療后以虛證為多,治療以補虛為主,清熱解毒、活血化瘀為輔。
[Abstract]:Ovarian cancer is a common gynecological malignant tumor with high incidence and poor prognosis. Surgery is a process of damage to qi, and chemotherapy drugs also have toxic effects on normal cells when they act on tumor cells, causing the corresponding toxic and side effects, such as bone marrow suppression, digestive tract reaction, neurotoxicity and so on. Make the body difficult to tolerate or even have to interrupt treatment. In recent years, there are more and more researches on TCM related treatment, which has a certain curative effect on the side effects of tumor chemotherapy, which can help the body to improve immunity and better cooperate with treatment. In this paper, a literature study on the treatment of ovarian cancer after chemotherapy was carried out in this paper. Objective: to study the literature on the treatment of ovarian cancer by traditional Chinese medicine (TCM) after chemotherapy in recent years, and to explore the understanding of the pathogenesis of postoperative chemotherapy of ovarian cancer and the rule of traditional Chinese medicine (TCM) in the treatment of ovarian cancer. Methods: using CNKI knowledge database, Wanfang data knowledge platform and Weipu Chinese science and technology periodical database as the retrieval tools, we searched for the literature of TCM clinical research on ovarian cancer from January 1990 to February 2014. The clinical literature of Chinese medicine combined with ovarian cancer chemotherapy was screened out. The database of traditional Chinese medicine used in literature was established with the contents of category, efficacy, sexual taste, meridian, frequency and so on. The database was established by using Excel software and classified statistics were carried out. Results: according to the data sources and retrieval methods, a total of 124 articles were obtained. According to the inclusion criteria mentioned in the previous article, 27 articles were selected to meet the criteria. 1201 cases were involved in all the literatures, 35 prescriptions were collected and 116 kinds of drugs were used. The drug appeared 410 times, the number of times used was 14225. 1. According to the syndrome types appeared in the literature, the most of the patients with ovarian cancer after chemotherapy were deficiency of Qi and Yin (35.22), followed by deficiency of Qi and Blood stasis (21.442), spleen deficiency of dampness (17.2442) and stagnation of dampness (17.24.2). According to the frequency of the drugs used, the top 10 places of drug use rate were Astragalus, Atractylodes macrocephala, Poria cocos, Codonopsis, Glycyrrhiza, Scutellaria barbata, Angelica sinensis, Coix seed, Curcuma. According to the classification of drugs, the most frequent occurrence of drugs was deficiency drugs (38.29), followed by heat-clearing drugs (15.61%) and blood circulation drugs (12.933.4%). According to the medicinal properties and classics, the most common drugs were flat drugs, sweet taste and spleen meridian. Conclusion: deficiency syndrome is the main treatment for ovarian cancer after chemotherapy, the main treatment is tonifying deficiency, clearing heat and detoxifying, activating blood circulation and removing blood stasis.
【學(xué)位授予單位】：北京中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2014
【分類號】：R737.31

【參考文獻】

相關(guān)期刊論文 前10條

1 夏親華;中藥扶正培本、化瘀解毒配合腹腔化療治療晚期卵巢癌[J];安徽中醫(yī)臨床雜志;1999年01期

2 馬靖,符乃陽,李玉梅,彭文烈,徐安龍;甘草提取物體外選擇性誘導(dǎo)幾種人腫瘤細胞凋亡[J];癌癥;2001年08期

3 楊曉葵,鄭芳,陳建華,高慶蕾,盧運萍,王世宣,王常玉,馬丁;凋亡相關(guān)蛋白的表達及Caspase-3活性改變與人卵巢癌細胞順鉑耐藥的關(guān)系[J];癌癥;2002年12期

4 劉明華;任美萍;李蓉;章卓;肖順漢;;川芎嗪對人卵巢癌順鉑耐藥細胞株COC1/DDP的逆轉(zhuǎn)作用研究[J];重慶醫(yī)學(xué);2011年20期

5 李瑞燕;高建平;;黨參粗多糖抗S_(180)腹水瘤小鼠腫瘤的初步研究[J];長治醫(yī)學(xué)院學(xué)報;2011年02期

6 吳春;徐力;;徐力教授治療卵巢癌[J];長春中醫(yī)藥大學(xué)學(xué)報;2013年03期

7 崔恒;昌曉紅;;生物治療在卵巢癌治療中的地位及其發(fā)展趨勢[J];中國婦產(chǎn)科臨床雜志;2012年05期

8 李明花;金佳鶴;;施志明治療卵巢癌的經(jīng)驗[J];河北中醫(yī);2008年09期

9 高振華;;孫秉嚴治療卵巢癌經(jīng)驗拾萃[J];河南中醫(yī);2009年05期

10 楊超;金泳海;鄒建偉;劉一之;朱曉黎;陳瓏;沈健;李智;倪才方;胡建銘;;術(shù)前介入性化療栓塞治療卵巢癌63例療效評估[J];介入放射學(xué)雜志;2011年05期

，

本文編號：2127017